Targeted drug capmatinib price

Capmatinib (Capmatinib) is an oral targeted drug that belongs to the category of tyrosine kinase inhibitors (TKI). It is used to treat a specific subset of non-small cell lung cancer (NSCLC), patients who carry METexon14 skipping mutations.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

METexon14 skipping mutations are rare but clinically important gene mutations that lead to aberrant activation of the MET receptor kinase. MET is an important receptor kinase involved in regulating biological processes such as cell proliferation, migration, and survival. When METkinase is abnormally activated, it may promote the growth and spread of cancer cells, leading to the progression of NSCLC.

Capmatinib works by inhibiting the activity ofMETkinase and interfering with the conduction of abnormal signaling pathways, thereby slowing down or inhibiting the proliferation and spread of cancer cells. It specifically targets NSCLC patients carrying MET exon 14 skipping mutations, providing a new treatment option for these specific patients.

In clinical trials, capmatinib has been shown to have a modest therapeutic effect in patients with advanced NSCLC carrying METexon14 skipping mutations. Subject to approval by the relevant regulatory authorities, capmatinib has been licensed for the treatment of this specific subpopulation of patients.

However, like all drugs, capmatinib may cause some side effects, so it should be comprehensively evaluated by a doctor before use and used in accordance with the doctor's instructions and recommendations.